New study tracks Real-World impact of fabry treatment in china

NCT ID NCT07187440

Recruiting now Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 200 Chinese children and adults with Fabry disease who are receiving routine treatment with Replagal (agalsidase alfa). The goal is to see how the therapy affects heart and kidney function over time, as well as quality of life and safety. Participants continue their normal care without extra study visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fabry disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FABRY DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Affiliated Drum Tower Hospital, Medical School of Nanjing University
RECRUITING

Nanjing, Jiangsu, 210008, China
Fuzhou University Provincial Affiliated Hospital
RECRUITING

Fuzhou, Fujian, 350001, China
Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China
Peking University First Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100034, China
Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, 100191, China
Second Hospital Of ShanXi Medical University
NOT_YET_RECRUITING

Taiyuan, Shanxi, '030001, China
ShanTou Central Hospital
RECRUITING

Shantou, Guangdong, 515031, China
The First Affiliated Hospital Of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China
The First Affiliated Hospital Of USTC (AnHui Provincial Hospital)
NOT_YET_RECRUITING

Hefei, Anhui, 230001, China
The First Affiliated Hospital With NanJing Medical University(JiangSu Province Hospital)
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210029, China
The First Affiliated Hospital of Xi 'an Jiaotong University
NOT_YET_RECRUITING

Xi'an, Shaanxi, 710061, China
The Second Affiliated Hospital ZheJiang University School Of Medicine
NOT_YET_RECRUITING

Hangzhou, Guangdong, 310009, China
The Second Affiliated Hospital of Harbin Medical University
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150086, China
The Second Affiliated Hospital of Xi 'an Jiaotong University
RECRUITING

Xi'an, Shaanxi, 710004, China
The Second Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, '050000, China
The University Of Hong Kong-ShenZhen Hospital
NOT_YET_RECRUITING

Shenzhen, Guangdong, 518053, China
TianJin Chest Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300222, China
West China Hospital of Sichuan University
NOT_YET_RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.